Q2 2020 13F Holders as of 6/30/2020
-
Type / Class
-
Equity / Common Stock, $0.01 par value per share
-
Shares outstanding
-
210M
-
Number of holders
-
155
-
Total 13F shares, excl. options
-
131M
-
Shares change
-
+8.47M
-
Total reported value, excl. options
-
$624M
-
Value change
-
+$86.6M
-
Put/Call ratio
-
0.33
-
Number of buys
-
100
-
Number of sells
-
-55
-
Price
-
$4.76
Significant Holders of BIOCRYST PHARMACEUTICALS INC - Common Stock, $0.01 par value per share (BCRX) as of Q2 2020
193 filings reported holding BCRX - BIOCRYST PHARMACEUTICALS INC - Common Stock, $0.01 par value per share as of Q2 2020.
BIOCRYST PHARMACEUTICALS INC - Common Stock, $0.01 par value per share (BCRX) has 155 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 131M shares
of 210M outstanding shares and own 62.4% of the company stock.
Largest 10 shareholders include STATE STREET CORP (15.6M shares), BlackRock Inc. (14.7M shares), BAKER BROS. ADVISORS LP (13.8M shares), VANGUARD GROUP INC (10.9M shares), CITADEL ADVISORS LLC (8.49M shares), MILLENNIUM MANAGEMENT LLC (6.57M shares), Eversept Partners, LP (4.85M shares), DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (4.46M shares), TWO SIGMA INVESTMENTS, LP (2.86M shares), and FMR LLC (2.56M shares).
This table shows the top 155 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.